AbSci Overview
- Founded
-
2011
- Status
-
Public
- Employees
-
213
- Stock Symbol
-
ABSI
- Investments
-
2
- Share Price
-
$1.73
- (As of Monday Closing)
AbSci General Information
Description
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 18105 SouthEast Mill Plain Boulevard
- Vancouver, WA 98683
- United States
+1 (360) 000-0000
AbSci Timeline
AbSci Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.73 | $1.72 | $1.53 - $9.09 | $159M | 92.4M | 484K | -$1.22 |
AbSci Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 108,067 | 501,703 | ||
| Revenue | 5,642 | 4,782 | 4,780 | 2,060 |
| EBITDA | (98,567) | (99,773) | (12,588) | (5,825) |
| Net Income | (110,599) | (100,960) | (14,353) | (6,584) |
| Total Assets | 339,387 | 426,195 | 88,569 | 19,471 |
| Total Debt | 22,138 | 20,011 | 14,500 | 6,016 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
AbSci Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AbSci Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the n
Drug Discovery
Vancouver, WA
213
As of 2022
00000
0.000
0000-00-00
00000000
00000
000000
lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla paria
0000 000000000
Dusseldorf, Germany
00
As of 0000
0000000000
000000
piscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000 000000000
San Carlos, CA
00
As of 0000
00000
000000000
00000
Add Comparison
AbSci Competitors (29)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NUMAFERM | Venture Capital-Backed | Dusseldorf, Germany | 00 | 0000000000 | ||
| 00000000 | Formerly VC-backed | San Carlos, CA | 00 | 00000 | 000000000 | 00000 |
| 00000 0000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Corporate Backed or Acquired | Richmond, CA | 000000000 - | |||
| 000000000 | Formerly VC-backed | Piscataway, NJ | 0000 | 00000 | 000000000 | 00000 |
AbSci Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AbSci Patents
AbSci Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021259323-A1 | Polypeptide cleavage methods | Pending | 20-Apr-2020 | 000000000 | |
| CA-3180693-A1 | Polypeptide cleavage methods | Pending | 20-Apr-2020 | 000000000 | |
| EP-4139329-A2 | Polypeptide cleavage methods | Pending | 20-Apr-2020 | 000000000 | |
| AU-2021218706-A1 | Proximity assay | Pending | 11-Feb-2020 | 0000000000 | |
| CA-3170531-A1 | Proximity assay | Pending | 11-Feb-2020 | G01N33/542 |
AbSci Executive Team (16)
AbSci Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Amrit Nagpal | Redmile Group | Board Member | 000 0000 |
| Daniel Gold Ph.D | AbSci | Board Member | 000 0000 |
| Daniel Rabinovitsj | AbSci | Board Member | 000 0000 |
| Gustavo Mahler Ph.D | Self | Board Member | 000 0000 |
| Ivana Magovcevic-Liebisch Ph.D | Self | Chairman & Board Member | 000 0000 |
AbSci Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
AbSci Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
AbSci Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 04-Jun-2021 | 0000000000 | 00000 | Drug Discovery | 0000 0000 |
| Denovium | 12-Jan-2021 | Merger/Acquisition | Decision/Risk Analysis | 0000 0000 |
AbSci Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 0000000 | Drug Discovery | Cambridge, MA | 0000 |
AbSci ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
25.55 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Commercial Services
Industry
00 of 430
Rank
00.00
Percentile
Business Support Services
Subindustry
00 of 159
Rank
00.00
Percentile
